May 18, 2021
Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit
May 10, 2021
Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress
May 3, 2021
Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting
April 21, 2021
Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors
March 11, 2021
Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021
March 9, 2021
Revolution Medicines to Participate in Upcoming Investor Conferences
March 2, 2021
Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress
February 18, 2021
Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences
February 8, 2021
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
February 3, 2021
Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock